ADRB3 and melanoma: Indeed, treatment with β-blockers, such as propranolol, a β-blocker targeting β1- and β2-ARs, or SR59230A and L-748337, both β3-AR antagonists, appears effective in reducing tumor growth in a mouse model of melanoma, as well as in increasing the overall survival of melanoma patients [2,3,4,5,6,7,8,11,12,19,20].